
STOPObesityAlliance
@stopobesity
STOP is a collaboration of public/private organizations, health providers, & consumers united to drive innovative & practical strategies that combat obesity.
ID: 59818694
http://stop.publichealth.gwu.edu/ 24-07-2009 16:07:51
10,10K Tweet
8,8K Followers
567 Following


Let’s talk about obesity—not with blame, but with understanding. It’s a chronic disease that requires real solutions. Read more in STOPObesityAlliance's: Developing a Comprehensive Benefit for Outcomes-based Obesity Treatment in Adults. stop.publichealth.gwu.edu/sites/g/files/…





Too many people face barriers to obesity care. It’s time for change! STOPObesityAlliance supports policies that expands access to affordable, effective treatment.



STOP's Cristy Gallagher took part in a great event last week that was a part of the SXSW in Austin TX and put on by The Economist . The discussion focused on the stigma and bias around obesity. Learn more about the work The Economist is doing here:  impact.economist.com/health/obesity…


Our March STOPObesityAlliance newsletter dives into the FDA's new draft guidance entitled “Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction.” Read more about the implications of the guidance and where to leave a comment at stop.publichealth.gwu.edu/LFD-mar25.

Congratulations to STOPObesityAlliance Research Assistant, Aden Belay, on her poster displayed at this year's Milken Institute SPH Research Days yesterday. She presented on the "Correlation Between Increased GLP-1 Medication Usage and Obesity Prevalence Across the Globe." Congrats Aden!


Our April STOPObesityAlliance newsletter features a guest letter from Joe Nadglowski of OAC, titled 'Concerns About Compounded GLP-1 Medications.' He highlights key issues around safety, access, and oversight. Read it here: stop.publichealth.gwu.edu/LFD-apr25.



As the availability and our understanding of obesity medications continue to grow, STOPObesityAlliance explores the trends and impacts of coverage of obesity treatment by employer health plans in our May newsletter. Read here: stop.publichealth.gwu.edu/LFD-may25



We commend U.S. Senator Bill Cassidy, M.D. & Senator Ben Ray Luján for reintroducing the Treat and Reduce Obesity Act (TROA) in the Senate yesterday. This bill expands access to obesity treatment by closing critical gaps in Medicare coverage by providing access to obesity medications and expanding IBT.